CHATSWORTH, Calif., Nov. 19, 2009 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, today announced that Chairman, President and Chief Executive Officer Cesar Garcia will present an overview of the Company at the 21st Annual Piper Jaffray Health Care Conference on Tuesday, December 1, 2009 at 2:30 p.m. Eastern time at the New York Palace Hotel in New York City.
An audio webcast of Mr. Garcia's presentation will be available live and by replay. To access the live audio webcast, go to the investor relations page of the IRIS website at: http://www.proiris.com/aboutus/investorrelations.php, 5-10 minutes before the webcast is scheduled to begin. The slides accompanying the presentation will also be available on the IRIS website. For those who are unable to listen to the live audio webcast, a replay of the presentation will be archived on the Company's website for 30 days following the conference.
About IRIS International, Inc.
IRIS International is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,400 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company is developing molecular diagnostic tests based on its Nucleic Acid Detection Immunoassay, or NADiA(R), platform, with applications in oncology and infectious disease. For more information, visit www.proiris.com.